Enzyme by Design logo — Protein engineering experts passionate about developing canc...

Enzyme by Design

Protein engineering experts passionate about developing cancer drugs that combat cancer without the collateral damage

Founded 2017 United States Chicago, United States 3 employees Biotechnology, Health Care

General Information

Company Name Enzyme by Design
Founded Year 2017
Location United States Chicago, United States +1
Founders / Decision Makers
Team member
Employees 3
Industries Biotechnology, Health Care
Social

Get notified when Enzyme by Design moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Enzyme by Design

Enzyme by Design (EbD) is a preclinical stage startup focused on designing and developing oncology biologics that are highly effective at exploiting weaknesses in cancers and eradicating tumor cells but with a clear focus on patient safety and reducing side effects. Using protein engineering expertise, EbD has created protein molecules targeting pediatric cancer as well as notoriously difficult to treat cancers like acute myeloid leukemia, pancreatic, liver, and ovarian cancers. The company's clinical strategy incorporates well-known drug mechanisms of action and patient genomic and epigenetic markers to ensure that only those patients likely to benefit greatly from their biologics will receive them. EbD's passion for developing cancer drugs that combat cancer without collateral damage addresses the critical need for improved cancer treatment options. Founded in 2017, the startup operates in the Biotechnology and Health Care industries. With a compelling slogan emphasizing their dedication to patient safety and innovative approach to cancer treatment, Enzyme by Design presents a promising investment opportunity.

Taxonomy: Protein engineering, Cancer drug development, Oncology biologics, Pediatric cancer treatment, Acute myeloid leukemia, Solid tumor treatment, Precision medicine, Drug mechanisms of action, Patient genomic markers, Epigenetic markers, Clinical strategy, Biologic therapies, Cancer treatment innovation, Patient safety, Reducing side effects

No funding data available for Enzyme by Design yet.

Get notified when Enzyme by Design raises funding

Enzyme by Design Alternatives & Competitors

Enzyme by Design vs
Pyxis Oncology
Pyxis Oncology United States

Charting a course to therapeutics for difficult-to-treat cancer.

Unknown
68 employees
Biotechnology, Health Care
Enzyme by Design vs

Pioneering the future of cancer detection with advanced protein bio-markers for comprehensive screen...

Series Unknown
1 employees
Biopharma, Biotechnology
Enzyme by Design vs

Pioneering the future of cancer treatment with innovative PI3K inhibitors.

Series B
Biotechnology, Health Care

FAQ About Enzyme by Design

Protein engineering experts passionate about developing cancer drugs that combat cancer without the collateral damage
Enzyme by Design was founded in 2017.
Enzyme by Design is headquartered in Chicago, United States.
Enzyme by Design operates in the following industries: Biotechnology, Health Care.
Enzyme by Design has approximately 3 employees.
Top alternatives and competitors to Enzyme by Design include Pyxis Oncology, Oncohealth CORP, Semafore Pharmaceuticals, Tradewind BioScience, Continuum Life Sciences. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Enzyme by Design and Pyxis Oncology are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Enzyme by Design and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

One analytics cookie (Google Analytics). Cookie Policy